Return to CBI Antibody Core Home Page
  Return to mouse list
    Return to mouse ( Mus musculus ) list


mouse ( Mus musculus )
Polyductin


Antibody Name/Abbreviation: Polyductin
CBI Antibody Core Code: A0503

"Lot" Number: 1 Position: 100(3960-4059)
% Identical Homology of Target to Mouse Protein: 100% (NP_694819.1| polycystic kidney and hepatic disease 1; polyductin; TIG multiple domains 1; tigmin)
Molecular Weight of fusion protein: N.A. KDa

Target sequence used to make this antibody:
ATPAPKIPRITCVPGSLAQQLTLQEPGNWQEAQQQLLRYQ
LAGRNQLLLLRPDLRQERKQGQEPSQLDKGSDCTGLSQEK
ATCIPTETFGLHTTPPETIQ






Sequence Name: Polyductin
Full name: Polyductin/Fibrocystin
UniGene Number: N.A.
Accession Number: AAN05018
Source organism: mouse ( Mus musculus )
Full length size (aa): 4059
NCBI information page: click here

Full length sequence:
MMLAWLVSLLSMEVLLLAKPYSSFQIEPAEGSLAGGTWITVVFDGLDRSI
LYPNNGSQLQIDLVSVAIPTLRIPCDVSPAFVDLPVVTCQTRSLPSEADA
GPYSLEIRSGEQVLGTPCPGSLDSCTFKFSKDQTPVLYQVYPASGVPGEV
VSVYGRVITTWLETFDPDVDYIESPLILEAREDKWLTPCSLINRQTGSCF
PIQEEHGLGNVQCRVEGDYIGSQNVSFSVFNKGRSMVHKEAWLISAKQEL
FLYQTYPEILSVFPKVGSLGGRTDIIITGDFFDPSARVTIAGIPCDIRYV
SPRKIECTTRAPGNEARLTAPQAGNRGLRFEVGDATKDVELTEATPGYRW
QIVPNASSPSGFWSKEGRPFRARLSGFFVAPQTNNYTFWIQADSQASLCF
SSSEEPRTKVEVASVGVGTADWFDSWEQIGNEGSWHQKTTKLELQGGAKY
YLEAEQHGIAPSRGMRIGVQIHNTWLNPDVVNTYLLEKHQIRARAQRLPE
IQVLHVSGKGNFFLTWGNVSSQPVPANATAQQIQTTIEELLVVKCNLAPF
SARVLLRLGFEQGLEGSRSDGVLTSSTEPFCGRFSLGQLGHLILIPEAAD
KGYQPDRYPYLCLAYRGHMNKTLDMTVSFLFGFQNIMKNITCDWSLTNPH
PESWQFTCINLWDTCLCHSEDLQSSLANTPLLVHRIDIRPVVPEAGLLYV
DEIILADTNVTVSQADSGRACPGGNVVESVSVVGVPPVYSISSWLAGCGS
ELPLITACSVSTEGTGDGSELIEVTAQRLQRTSPPLGGHFFLYLSDTVIT
DVPVRMSARQLHKLLQDSADESTSGYLNAGDFTVTEDLNSCYEHVWTLSW
TTQTGDLPNFIRVSDQNLTGVNPTVTARVVYDGGVFLGPIFGDMLATANQ
QTQVAVQVNDIPAYCSGSCSFQYQQESTPSVDHVWYSLGSDVNLLVHFTG
TGFPRDTQFLQVTVNKTSCEVLFSNETNVACELALLPVGVHQIFMLVIPS
GLAVNASGEDLLLHVEPRLDAVEPSTAAEIGGRWVTLRGSSLEGVSLVLF
GTQSCVIDAIRSNSQQIQCKVPPRGKVGYTVNVTVISGDHSTVLARAFTY
VSSLNPVIVSLSRNRSSIAGGEILFLGMSLLVNYTDLDVQIHVQDTSAQV
LSQTAWGLEVVLPPLVPGIHAISAFINGVSIRSQGVDLYIQYLTEVFSVE
PCSGSLLGGTLLNLLGTGLGRDPALIRVLVDNHPCDIVNLTEVNIWCETP
PAVLPPRADVLTVPASVEIWAGNTSFFHGPSLVGKGFTFTYEAAATPVVT
AMWGEFRNNSVRFYVEGSNISDSVILLGSLKCELEVQFFGDSMNLFGCFF
PLHSLEAGVYTLQVRHKRMGFANMSVVPQKFELSPQIIAIFPTHGSKCGG
TVLTVKGMAFSSRKRSVHVDISGPFACMILSLEDHTVLCQTRFVGDQFSE
ASLALNITVLVNGLTSKCKGNCTLFIEEAATPNVDALTISISGSLTMVLM
RGRRLATTADEPIAFVDDQLPCHTTFFNTSHVACQIRDLAPGFHYLSAVH
TSAGYACLNSVSRNFFIVPQVLDYFPKDFSIHGGSLLMIKGTALRGWKAT
VVYVGRQACLTVNISSDFIQCIVPAGNGSAALEIDVDGVLYHIGLVDYSS
IFTPELLSVSRSQDILTFTVARISGAANVDIFIGTSPCLGVAGNRTVLQC
MVPLLPAGEYLVTGYDHSRGWASSTLILVLRATVTSVTKNYGCLGGRLLH
VLGAGFSPGNISAAVCGAPCQVLANATVSAFSCLVLPLDVSLAFLCDLRH
AEDSCKVRSSTYLQCDLTVSMGTERLPGSWPYVYLCEESSLCLFEPDHWT
ESVFPSFSGLFLSPKVERDEVLIYNSSCNITMETEAEMECEMPNQPITAK
ITEIQKSWGQNTQGNFSFQFCRRWSRPHSWFPQRVPHDGDSVTVETGHLL
LLDANTSFLNSLHIKGGKLIFMDPGPIELRAHSILITDGGELHIGSEEKP
FQGKARIKIYGSVHSTPFFPYGVKFLAVRNGTLSLHGSVPEVTVTYLQAA
AHAGDKVLTLGEAVDWKPGDEAVITSGMTVAGAEATEVVVVETVHNADLH
LRNPLRYSYDFRENWVAGENPILKPTVALLSRNIIIQGNFTLERVKLLNS
CQEANTAKGNLKHCLYSKSEKMLGARDLGARVIIQSFPEEPSFVKLKGVQ
FRDLGQAFHKHLSSLALVGAMRGSYIQSCSVWNSFSRGLSMHRTWGLKVD
SNVFYKIVGHALLLGSYLDGRFSTSETVTGRKNGWWEQGSTIRNNVIISV
SAAEGLSGSEMLAPAGIYTFSPTNVMEGNRVCAAGYGYVFHLVTSQTLQA
PLLSFNWNTAHSCTRYGLLVYPKFQPPWNNDTGFTLFQNFMVWGSAGGAQ
IFRSNNLHLKNFQVYACRDFGIDILESDANTLITDSFLLGHFTHKGSLCM
SAGIKTPQRWELTISNTTFVNFDGNCVAIRTCSGCFQGQGGYTVKTRQLK
FVNSSNLVAFPFPHAAVLEDLDGSLSGKNGSHVLASMETLSDTCLTNASF
SQIVPGSVCGEAVLFHRMSIALANSLDVPKNLTITDISNKTITVNYVEDT
LSNYYGWMALLLDQETYSLQFESPWMNRSLQYSATFDSFAPGNYLLIMHR
DLPPYPDILLRCGSQVGHSLPFHPLPSQDRACDWFFNRQLRQLTYLVSGE
GQVKVFLQLKPGVPPSVSASTSVPESASRWSLPETWQDVEKGWGGYNHTI
PGPGDDVLILPNKTVLVDTDLPVLRCLYVMGTLEFPVDRSNVLSVACLLI
AGGELKVGTLENPLEKDQRLLIFLRASEEVVCDYFEGIHVDPGTIGVYGK
LRLHSAYPKKSWVHLGADIAPGNERIIVHNAVDWQPHDTIVLSSSSYEAH
EAEVLTVKEVKGHHIRIYERLKHRHIGSTHTMEDGQQVHLAAEVGLLTRN
IRIQPDSSCRGRLLVGSFRKSSGEDFSGVLQLLNVEIQNMGLPLYSSIEF
TGVSAGSWVISSTVHQSCSVGIHASSSHGVILTDNVVFGTNGHGIDVEGQ
NYSLTNNLVILTMQSANSSPWVAGIKVNYAEDIILHGNVVAGSERLGFHV
GGHGCSSEVLWSDNVVHSSLHGLHLYKKHESNNCTGVSGFMAFKNFDYGA
MVQTENSVDIQNITLVDNTVGLLAITYVSSALLSSVSTVQITLRNSVIVA
TSSSFDCIHDRKAPQSANWTSTDRAPSNPRGGRIGILWPVSASEPNAWPQ
EPWHKVRSHHSVPGIMKLQDVTFSSFVKSCYSNDLDVCILPNEYSTGVMY
PITAERTRMLGIKDKNKFYFPVLQSSKDLVGTICPTLVCEYPRKYLFTDL
DGRTLGLPPPVSVFPRTEEEWTGSFLNTGIFREEQKCTFRAMNQGFFCKQ
TEHAVLILDNVDATWTIPKSHPLVSVTNGFVDTFSIVKDSDLCPPTSSLS
TFYSILPTRQMTKVCFPEQTPPFLRFLLLGNQRASKLILAVFYNEIQSPH
VFLDKSFIPPTPLESAFSLLAEPSGANYFDIMNNLLYVVLQGEEPVEIHS
SVSIHLALTVTFSVLEKGWERAMLESLSDFFQIDPNQIRLTLEMPGNKET
LEAIANSERKRKRNCPSVTCGGPSIRYGQRRPLMAEMTSLKITPATTLET
FSKVIVIEVGDLPNIRNSEPIQSLPSNRLQRLVNQVITAQQTGALENVLG
MTVGALLVTQSKGVTGYRNASSLITGNLIYTRPSELSILVQPSDGEVGIE
LPVQPRLVFLDEKNERVESLGLPSEPWIISVSLEGASESVLKGCTLAETR
DGYVTFSRLAVLISGSNWHLFFTVISPPGTNFTARSRTFVVLPVASKERS
TIILALSLCSVASWVALSCLVCCWFKKSKTRKIKPEDISESQAKEQKKNT
HNSSKPRGLQAKTAKENTLMGEDMRMKVMQGMQSQFPQHSMDGVSKRKVS
RLAVTGERTATPAPKIPRITCVPGSLAQQLTLQEPGNWQEAQQQLLRYQL
AGRNQLLLLRPDLRQERKQGQEPSQLDKGSDCTGLSQEKATCIPTETFGL
HTTPPETIQ





Questions? Click here for answers.


© Monday, February 16, 2009 by the CBI Antibody Core and the Center for Biomedical Inventions, University of Texas Southwestern Medical School.